Drupal.behaviors.print = function(context) {window.print();window.close();}>
FDA Issues Guidance Doc on Reclassifying NAT TB Tests as 'Moderate Risk'
March 21, 2012
FDA Issues Guidance Doc on Reclassifying NAT TB Tests as 'Moderate Risk'
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
FDA Issues Draft Guidance on Molecular Dx Instruments with Combined Functions
April 10, 2013 / GenomeWeb Daily News
FDA Offers Guidance for MRSA Tests
January 5, 2011 / GenomeWeb Daily News
FDA Clears Luminex xTAG Gastrointestinal Panel on MagPix Platform
April 15, 2013 / GenomeWeb Daily News
FDA Clears BD's C. difficile Assay for BD Max System
April 9, 2013 / GenomeWeb Daily News
FDA Recategorizes Meridian's Molecular Strep A and B Assays as 'Moderate Complexity' Tests
March 19, 2013 / GenomeWeb Daily News